Evidence map›Paper›PMID 39260845›Full record

ArticleBMJ open2024

Assessing the effect of anthocyanins through diet and supplementation on cognitive function in older adults at risk for dementia: protocol for a randomised controlled trial.

Vinicius do Rosario, Elnaz Lorzadeh, Henry Brodaty, Kaarin J Anstey, Karina Chan, Steven Roodenrys, Katherine Kent, Vida Bliokas, Lyn Phillipson, Katrina Weston-Green and 6 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Vinicius do RosarioSchool of Medical, Indigenous and Health Sciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia.ORCID 0000-0002-7613-9397
Elnaz LorzadehSchool of Medical, Indigenous and Health Sciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia.
Henry BrodatyCentre for Healthy Brain Ageing, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
Kaarin J AnsteyNeuroscience Research Australia, University of New South Wales, Sydney, New South Wales, Australia.
Karina ChanCentre for Healthy Brain Ageing, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
Steven RoodenrysSchool of Psychology, Faculty of Arts and Social Science, University of Wollongong, Wollongong, New South Wales, Australia.
Katherine KentSchool of Medical, Indigenous and Health Sciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia.
Vida BliokasSchool of Psychology, Faculty of Arts and Social Science, University of Wollongong, Wollongong, New South Wales, Australia.
Lyn PhillipsonSchool of Health and Society, Faculty of Arts and Social Science, University of Wollongong, Wollongong, New South Wales, Australia.
Katrina Weston-GreenSchool of Medical, Indigenous and Health Sciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia.
Monique E FrancoisSchool of Medical, Indigenous and Health Sciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia.ORCID 0000-0001-9518-0750
Xiaotao JiangMicrobiome Research Centre (MRC), University of New South Wales, Sydney, New South Wales, Australia.
Jenson GeorgeDepartment of Agriculture and Fisheries, Queensland Government, Brisbane, Queensland, Australia.
Jan PotterDivision of Aged Care, Rehabilitation and Palliative Care, Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia.
Marijka J BatterhamNational Institute for Applied Statistical Research Australia and the Statistical Consulting Centre, School of Mathematics and Applied Statistics, University of Wollongong, Wollongong, New South Wales, Australia.ORCID 0000-0002-9520-6508
Karen CharltonSchool of Medical, Indigenous and Health Sciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, New South Wales, Australia karenc@uow.edu.au.ORCID 0000-0002-8044-444X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPromising evidence is emerging for the procognitive, anti-inflammatory and neuroprotective properties of dietary flavonoids, particularly anthocyanins that provide red, purple and blue plant pigments. METHODS AND ANALYSIS: The 'Food for Thought' study is a multicentre, 6-month randomised, parallel 3-arm clinical trial. Its primary aim is to investigate whether anthocyanin consumption, either through diet or supplementation, can prevent memory loss progression and improve inflammatory and cardiovascular health in older adults at risk for dementia. Eligible participants will include those aged 60-85 years with a diagnosis of amnestic mild cognitive impairment or with a self-referral of memory concerns and scoring ≤13 on the Memory Index Score within the Telephone Montreal Cognitive Assessment screening test. Participants will be randomised to one of three arms: High anthocyanin ('purple foods') diet (aiming for a target of 250 mg anthocyanins/day); freeze-dried product derived from blackcurrants (250 mg anthocyanins/day); or control (coloured maltose powder). The primary outcome is auditory anterograde memory functioning assessed by the Buschke and Grober Free and Cued Selective Reminding Test-Immediate Recall. Secondary outcomes are additional cognitive functions including processing speed, working memory, aspects of executive functioning (attentional shifting and word generativity) and premorbid estimate as well as subjective memory problems and self-reported depression symptoms. Additional secondary outcomes are blood pressure, inflammatory biomarkers, brain-derived neurotrophic factor, fatty acid profile, apolipoprotein E and polyphenol metabolites, gut microbiota composition and function and vascular and microvascular endothelial function tests. Repeated measures analysis of variance and/or mixed linear modelling will evaluate changes over time, with the inclusion of covariates. ETHICS AND DISSEMINATION: Ethics approval has been obtained from the Greater Western Human Research Ethics Committee (2021/ETH12083). A Consumer Advisory Group was established to guide and review the protocol and dissemination strategy. The results of this trial are intended to be published in a peer-reviewed journal. TRIAL SPONSOR: National Health and Medical Research Centre Dementia Collaborative Research Centre.Start date of clinical trial: 02 September 2022.Expected end date: 11 October 2024. TRIAL REGISTRATION NUMBER: ACTRN12622000065796.

Indexed as

AnthocyaninsCognitionCognitive DysfunctionDementiaDietary SupplementsRandomized Controlled Trials as TopicAgedAged, 80 and overFemaleHumansMaleMiddle AgedMulticenter Studies as TopicAnthocyaninsagingclinical trialcognitiondementianutrition & dietetics

Identifiers

PMID39260845
PMCPMC11409387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.